SUNRISE Trial for Oral Steroid Dependent Asthma
Trial Objectives
People with severe asthma are often dependent on oral corticosteroids, such as prednisone, to treat their condition. Researchers are currently investigating whether a new biologic treatment called tezepelumab may help to reduce or remove the need for these steroid medications.
In this study, tezepelumab will be compared against a treatment that does not contain any active medication, called a placebo. Either tezepelumab or the placebo will be given as an injection to study participants.
Who Can Participate
Adults ages 18-80 with a documented asthma diagnosis for at least 1 year requiring daily oral steroids for at least 6 months in addition to inhaled steroid treatments. Other criteria will be evaluated to see if you may participate in this study.
Age: 18-80 Gender: Any
Estimated Time Commitment
14 visits over approximately 12 months. Most visits will last about 2 hours, but a few could take up to 4 hours.
Payment & Reimbursement
Payment: Provided
Travel Reimbursement: Not Available
Trial Location
National Jewish Main Campus, Denver, CO
Trial Sponsors
AstraZeneca
Principal Investigators
Michael E. Wechsler, MD, MMSc